背景:革兰氏阴性菌幽门螺杆菌,幽门螺杆菌,与严重的消化系统疾病有关。然而,由于耐药性,细菌根除的有效性正在下降。一种强效的抗H.幽门螺杆菌活性由天然抗菌肽pexiganan显示。
目的:本研究旨在评估培西加聚糖及其脂质液晶(LLC)在小鼠中诱导幽门螺杆菌的有效性。
方法:在本实验研究中,首先在C57BL/6小鼠中诱导幽门螺杆菌感染。其次,研究了培西加南及其LLC制剂的抗菌功效,以消除幽门螺杆菌感染.
结果:单独使用培西加南肽不能完全根除幽门螺杆菌感染。然而,在LLC制剂中掺入pexiganan导致幽门螺杆菌的消除增加。在H&E压力下,与安慰剂相比,培西加南-LLCs制剂显示出最小的粘膜改变和较低的胃炎性细胞浸润量.
结论:在所有测试浓度下,克拉霉素比培西加南更有效。此外,在小鼠模型中,与单用pexiganan相比,负载pexiganan的LLC在治疗幽门螺杆菌感染方面表现出优异的疗效.该制剂可以增强幽门螺杆菌清除率,同时减轻不良反应,通常与常规药物有关,导致一个可行的替代目前的治疗方案。
The Gram-negative bacterium Helicobacter pylori, H. pylori, is associated with significant digestive disorders. However, the effectiveness of bacterial eradication is declining due to drug resistance. A potent anti-H. pylori activity is shown by the natural antimicrobial peptide pexiganan.
The current study aimed to evaluate the effectiveness of pexiganan and its lipid-liquid crystals (LLCs) in inducing Helicobacter pylori in mice.
In this experimental study, H. pylori infection was first induced in C57BL/6 mice. Secondly, the antibacterial efficacy of pexiganan and its LLCs formulations was investigated to eliminate H. pylori infection.
The H. pylori infection could not be completely eradicated by pexiganan peptide alone. However, incorporating pexiganan within the LLC formulation resulted in an increased elimination of H. pylori. Under the H&E strain, the pexiganan-LLCs formulation revealed minimal mucosal alterations and a lower amount of inflammatory cell infiltration in the stomach compared to the placebo.
Clarithromycin was more effective than pexiganan at all tested concentrations. Furthermore, the pexiganan-loaded LLCs exhibited superior efficacy in curing H. pylori infection in a mouse model compared to pexiganan alone. This formulation can enhance H. pylori clearance while mitigating the adverse effects, typically associated with conventional drugs, leading to a viable alternative to current treatment options.